Literature DB >> 7515093

Quantitation of soluble fibrinogen binding to platelets by fluorescence-activated flow cytometry.

N Faraday1, P Goldschmidt-Clermont, K Dise, P F Bray.   

Abstract

Soluble fibrinogen binding to agonist-stimulated blood platelets is the essential physiologic function of the glycoprotein IIb-IIIa (GPIIb-IIIa) receptor. We describe a method of quantifying this receptor-ligand interaction by using flow cytometry to detect the binding of fluorescein-labeled fibrinogen to activated platelets. Fibrinogen conjugated with fluorescein isothiocyanate (FITC-FGN) was structurally and functionally indistinguishable from native fibrinogen when analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, thrombin clottability, and receptor affinity studies. Platelet samples, at a concentration of 2 x 10(7) ml, were incubated with FITC-FGN and activated with adenosine diphosphate (ADP) before cytometric acquisition of fluorescence and scatter data. ADP-induced binding of soluble FITC-FGN to platelet GPIIb-IIIa was specific, time dependent, and saturable. Cytometric analysis of FITC calibration beads allowed generation of standard curves relating bead fluorescence intensity to the number of fluorescein equivalents per bead. With this information, platelet fluorescence intensity was converted into the number of FITC-FGN molecules bound per platelet. Such quantitative analysis of fibrinogen binding yielded a dissociation constant of 2.48 +/- 0.5 x 10(-7) mol/L and a maximum fibrinogen binding capacity of 42, 124 +/- 5, 628 molecules per platelet (mean +/- SEM), which are comparable to published results with radioligand assays. The simplicity, sensitivity, and quantifiability of this method may make it a useful technique for basic and clinical research involving GPIIb-IIIa function.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7515093

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  11 in total

1.  The Pl(A2) polymorphism of integrin beta(3) enhances outside-in signaling and adhesive functions.

Authors:  K V Vijayan; P J Goldschmidt-Clermont; C Roos; P F Bray
Journal:  J Clin Invest       Date:  2000-03       Impact factor: 14.808

2.  Tests of the extension and deadbolt models of integrin activation.

Authors:  Jieqing Zhu; Brian Boylan; Bing-Hao Luo; Peter J Newman; Timothy A Springer
Journal:  J Biol Chem       Date:  2007-02-13       Impact factor: 5.157

3.  Glanzmann thrombasthenia. Cooperation between sequence variants in cis during splice site selection.

Authors:  Y Jin; H C Dietz; R A Montgomery; W R Bell; I McIntosh; B Coller; P F Bray
Journal:  J Clin Invest       Date:  1996-10-15       Impact factor: 14.808

4.  Pharmacodynamic characterization of the interaction between abciximab or tirofiban with unfractionated or a low molecular weight heparin in healthy subjects.

Authors:  U Klinkhardt; J Graff; D Westrup; C M Kirchmaier; H U Esslinger; H K Breddin; S Harder
Journal:  Br J Clin Pharmacol       Date:  2001-09       Impact factor: 4.335

5.  Platelet CD62 expression and PDGFAB secretion in patients undergoing PTCA and treatment with abciximab.

Authors:  J Graff; D Andries; M Elsner; D Westrup; S Bassus; N Franz; U Klinkhardt; S Harder
Journal:  Br J Clin Pharmacol       Date:  2001-06       Impact factor: 4.335

6.  Crossreactivity of Human versus Swine Platelet Surface Antigens Is Similar for Glycoproteins Ib and IIIa, but Not for the Glycoprotein IIb/IIIa Complex.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1998       Impact factor: 2.300

7.  Dynamic regulation of fibrinogen: integrin αIIbβ3 binding.

Authors:  Roy R Hantgan; Mary C Stahle; Susan T Lord
Journal:  Biochemistry       Date:  2010-11-02       Impact factor: 3.162

8.  Platelet fibrinogen in the patients with idiopathic bleeding platelet disorder.

Authors:  L Yang; D Shen; A Wang; W Wei; Z Liu; R Yang; Y Yang; Y Zhang
Journal:  J Tongji Med Univ       Date:  2000

9.  Quantitative detection of platelet GPIIb-IIIa receptor antagonist activity using a flow cytometric method.

Authors:  L J Green; P Marder; S L Um; J A Jakubowski; J B Lawrence
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

10.  Eptifibatide-induced thrombocytopenia and thrombosis in humans require FcgammaRIIa and the integrin beta3 cytoplasmic domain.

Authors:  Cunji Gao; Brian Boylan; Dan Bougie; Joan C Gill; Jessica Birenbaum; Debra K Newman; Richard H Aster; Peter J Newman
Journal:  J Clin Invest       Date:  2009-02-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.